BidaskClub lowered shares of Akorn (NASDAQ:AKRX) from a sell rating to a strong sell rating in a research report sent to investors on Thursday morning.
A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Akorn from a hold rating to a strong sell rating in a research note on Friday, August 25th. Jefferies Group set a $34.00 target price on Akorn and gave the stock a hold rating in a research note on Sunday, October 29th. Piper Jaffray Companies set a $34.00 target price on Akorn and gave the stock a hold rating in a research note on Tuesday, August 29th. Finally, Royal Bank of Canada reaffirmed a hold rating and issued a $34.00 target price on shares of Akorn in a research note on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $30.71.
Shares of Akorn (NASDAQ:AKRX) traded down $0.02 on Thursday, hitting $32.20. The company’s stock had a trading volume of 1,226,100 shares, compared to its average volume of 2,684,062. Akorn has a twelve month low of $17.74 and a twelve month high of $34.00. The firm has a market cap of $4,029.77, a P/E ratio of 20.01, a PEG ratio of 2.01 and a beta of 1.33. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92.
A number of institutional investors have recently made changes to their positions in AKRX. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Akorn by 22.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock valued at $108,000 after acquiring an additional 599 shares during the period. Victory Capital Management Inc. boosted its holdings in Akorn by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock valued at $140,000 after acquiring an additional 626 shares during the period. LMR Partners LLP purchased a new position in Akorn during the 3rd quarter valued at about $200,000. Cubist Systematic Strategies LLC purchased a new position in Akorn during the 2nd quarter valued at about $209,000. Finally, World Asset Management Inc purchased a new position in Akorn during the 2nd quarter valued at about $210,000. Institutional investors own 73.53% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/15/akorn-akrx-lowered-to-strong-sell-at-bidaskclub.html.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
What are top analysts saying about Akorn? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akorn and related companies.